مکتبة رقمیه للعلوم الطبيه
Your cart is empty.
  • Cart
  • Lists
    Your lists Log in to create your own lists
  • Log in to your account
  • Your cookies
  • Search history
  • Advanced search
  • Authority search
  • Tag cloud
  • Library

Log in to your account

  1. Home
  2. Details for: Afatinib demonstrates remarkable activity against HER2-amplified uterine serous endometrial cancer in vitro and in vivo.
Normal view MARC view ISBD view

Afatinib demonstrates remarkable activity against HER2-amplified uterine serous endometrial cancer in vitro and in vivo. [electronic resource]

By:
  • Schwab, C L
Contributor(s):
  • Bellone, S
  • English, D P
  • Roque, D M
  • Lopez, S
  • Cocco, E
  • Nicoletti, R
  • Bortolomai, I
  • Bonazzoli, E
  • Ratner, E
  • Silasi, D-A
  • Azodi, M
  • Schwartz, P E
  • Rutherford, T J
  • Santin, A D
Producer: 20150109Description: 1750-6 p. digitalISSN:
  • 1532-1827
Subject(s):
  • Adult
  • Afatinib
  • Aged
  • Aged, 80 and over
  • Animals
  • Apoptosis -- drug effects
  • Cell Cycle -- drug effects
  • Cell Proliferation -- drug effects
  • Cystadenocarcinoma, Serous -- drug therapy
  • Endometrial Neoplasms -- drug therapy
  • Female
  • Humans
  • Immunoenzyme Techniques
  • In Situ Hybridization, Fluorescence
  • In Vitro Techniques
  • Mice
  • Mice, SCID
  • Middle Aged
  • Phosphorylation -- drug effects
  • Quinazolines -- pharmacology
  • Receptor, ErbB-2 -- genetics
  • Signal Transduction -- drug effects
  • Tumor Cells, Cultured
  • Uterine Neoplasms -- drug therapy
  • Xenograft Model Antitumor Assays
Online resources:
  • Available from publisher's website
In: British journal of cancer vol. 111
Tags from this library: No tags from this library for this title. Log in to add tags.
Star ratings
    Cancel rating. Average rating: 0.0 (0 votes)
  • Holdings ( 0 )
  • Title notes ( 1 )
  • Comments ( 0 )
No physical items for this record

Publication Type: Journal Article

There are no comments on this title.

Log in to your account to post a comment.
Browse results Close
Previous
Back to results
Next
  • 2301
  • 2302
  • 2303
  • 2304
  • 2305
  • 2306
  • 2307
  • 2308
  • 2309
  • 2310
  • 2311
  • 2312
  • 2313
  • 2314
  • 2315
  • 2316
  • 2317
  • 2318
  • 2319
  • 2320
  • 2301 Interactions of T helper cells with fibroblast-like synoviocytes: up-regulation of matrix metalloproteinases by macrophage migration inhibitory factor from both Th1 and Th2 cells.
    by Schurigt, Uta
  • 2302 A new class of isothiocyanate-based irreversible inhibitors of macrophage migration inhibitory factor.
    by Ouertatani-Sakouhi, Hajer
  • 2303 Interleukin-1 stimulates macrophage migration inhibitory factor secretion in ectopic endometrial cells of women with endometriosis.
    by Herrmann Lavoie, Catherine
  • 2304 Functional promoter polymorphisms of the macrophage migration inhibitory factor gene in gastric carcinogenesis.
    by Arisawa, Tomiyasu
  • 2305 Exhaustion is associated with low macrophage migration inhibitory factor expression in patients with coronary artery disease.
    by Kwaijtaal, Martijn
  • 2306 UVA induces granzyme B in human keratinocytes through MIF: implication in extracellular matrix remodeling.
    by Hernandez-Pigeon, Hélène
  • 2307 Activity-Based Proteome Profiling Probes Based on Woodward's Reagent K with Distinct Target Selectivity.
    by Qian, Yong
  • 2308 Relationship Between Serum Macrophage Migration Inhibitory Factor Level and Insulin Resistance, High-Sensitivity C-Reactive Protein and Visceral Fat Mass in Prediabetes.
    by Bilgir, Oktay
  • 2309 [EFFECT OF MACROPHAGE MIGRATION INHIBITORY FACTOR ON VASCULAR REPAIR OF STEROID-INDUCED AVASCULAR NECROSIS OF FEMORAL HEAD IN VITRO].
    by Ma, Jun
  • 2310 Comparative study of cytotoxic T-lymphocytes and producers of the macrophage migration inhibition factor (MIF) in the H-2 system.
    by Brondz, B D
  • 2311 Cell-mediated immunity to soluble and particulate inhaled antigens.
    by Hill, J O
  • 2312 In vivo studies on the cellular source of migration inhibitory factor in mice with delayed hypersensitivity.
    by Salvin, S B
  • 2313 [Cell-mediated immune response in juvenile diabetes].
    by Karmazsin, L
  • 2314 Studies on mediator production by highly purified human T and B lymphocytes.
    by Rocklin, R E
  • 2315 Effect of macrophage migration inhibitory factor on migration of allogeneic and xenogeneic macrophages.
    by Tsai, L C
  • 2316 Infection and allergy.
    by Bristow, V G
  • 2317 Migration inhibition factor secreting human T-cell lines reactive to PPD: a study of their antigen specificity, MHC restriction and the use of Epstein-Barr virus-transformed B-cell lines as requirement for antigen-presenting cells.
    by Vyakarnam, A
  • 2318 Modulation of macrophage functions by lymphokines.
    by Sorg, C
  • 2319 Crystal structure of the macrophage migration inhibitory factor from rat liver.
    by Suzuki, M
  • 2320 Transcriptional activation of the macrophage migration-inhibitory factor gene by the corticotropin-releasing factor is mediated by the cyclic adenosine 3',5'- monophosphate responsive element-binding protein CREB in pituitary cells.
    by Waeber, G
Close

Afatinib demonstrates remarkable activity against HER2-amplified uterine serous endometrial cancer in vitro and in vivo.

APA

Schwab C. L., Bellone S., English D. P., Roque D. M., Lopez S., Cocco E., Nicoletti R., Bortolomai I., Bonazzoli E., Ratner E., Silasi D., Azodi M., Schwartz P. E., Rutherford T. J. & Santin A. D. (20150109). Afatinib demonstrates remarkable activity against HER2-amplified uterine serous endometrial cancer in vitro and in vivo. : British journal of cancer.

Chicago

Schwab C L, Bellone S, English D P, Roque D M, Lopez S, Cocco E, Nicoletti R, Bortolomai I, Bonazzoli E, Ratner E, Silasi D-A, Azodi M, Schwartz P E, Rutherford T J and Santin A D. 20150109. Afatinib demonstrates remarkable activity against HER2-amplified uterine serous endometrial cancer in vitro and in vivo. : British journal of cancer.

Harvard

Schwab C. L., Bellone S., English D. P., Roque D. M., Lopez S., Cocco E., Nicoletti R., Bortolomai I., Bonazzoli E., Ratner E., Silasi D., Azodi M., Schwartz P. E., Rutherford T. J. and Santin A. D. (20150109). Afatinib demonstrates remarkable activity against HER2-amplified uterine serous endometrial cancer in vitro and in vivo. : British journal of cancer.

MLA

Schwab C L, Bellone S, English D P, Roque D M, Lopez S, Cocco E, Nicoletti R, Bortolomai I, Bonazzoli E, Ratner E, Silasi D-A, Azodi M, Schwartz P E, Rutherford T J and Santin A D. Afatinib demonstrates remarkable activity against HER2-amplified uterine serous endometrial cancer in vitro and in vivo. : British journal of cancer. 20150109.

  • Print
  • Cite
  • Add to your cart (remove)
  • Save record
    BIBTEX Dublin Core MARCXML MARC (non-Unicode/MARC-8) MARC (Unicode/UTF-8) MARC (Unicode/UTF-8, Standard) MODS (XML) RIS ISBD
  • More searches
    Search for this title in:
    Other Libraries (WorldCat) Other Databases (Google Scholar) Online Stores (Bookfinder.com) Open Library (openlibrary.org)

Exporting to Dublin Core...

Visit web site